Abstract
Aerosol delivery of asthma medications maximizes local effects in the lung and minimizes systemic effects compared with oral therapy. Both corticosteroids and bronchodilators are available in a variety of delivery devices for the treatment of asthma. The 1987 Montreal protocol requiring the phasing out of the chlorofluorocarbon (CFC) propellant in commonly used pressurized metered-dose inhalers (pMDIs) provided an impetus for the development of new technologies for the delivery of inhaled asthma medications. For pMDIs, CFC has been replaced with hydrofluoroalkane (HFA) propellant. New types of dry powder inhalers (DPIs) and nebulizers, aerosol delivery devices that do not use propellants, also have been introduced. Drug delivery varies based on the device type, the product formulation and patient-related factors. Thus, drug delivery can differ when the same medication is delivered via an HFA pMDI, a CFC pMDI, a DPI or a nebulizer. Even among the same type of device (eg. DPIs, pMDIs), inhaler designs and drug formulations differ. Drug and device selection should be based on consideration of the patients ability to use the device properly, the availability of a desired drug or drugs (ie. maintenance and rescue) in a particular inhaler device and patient preference. This review describes key characteristics for each device type, explains differences in markers of lung deposition, lists potential advantages and disadvantages of the different devices and discusses how these and other factors need to be considered when selecting an inhaler device that meets the individual needs of a patient.
Keywords: aerosol devices, asthma therapy, pMDI, MDI, HFA, nebulizers
Current Drug Delivery
Title: Aerosol Devices and Asthma Therapy
Volume: 6 Issue: 1
Author(s): William Berger
Affiliation:
Keywords: aerosol devices, asthma therapy, pMDI, MDI, HFA, nebulizers
Abstract: Aerosol delivery of asthma medications maximizes local effects in the lung and minimizes systemic effects compared with oral therapy. Both corticosteroids and bronchodilators are available in a variety of delivery devices for the treatment of asthma. The 1987 Montreal protocol requiring the phasing out of the chlorofluorocarbon (CFC) propellant in commonly used pressurized metered-dose inhalers (pMDIs) provided an impetus for the development of new technologies for the delivery of inhaled asthma medications. For pMDIs, CFC has been replaced with hydrofluoroalkane (HFA) propellant. New types of dry powder inhalers (DPIs) and nebulizers, aerosol delivery devices that do not use propellants, also have been introduced. Drug delivery varies based on the device type, the product formulation and patient-related factors. Thus, drug delivery can differ when the same medication is delivered via an HFA pMDI, a CFC pMDI, a DPI or a nebulizer. Even among the same type of device (eg. DPIs, pMDIs), inhaler designs and drug formulations differ. Drug and device selection should be based on consideration of the patients ability to use the device properly, the availability of a desired drug or drugs (ie. maintenance and rescue) in a particular inhaler device and patient preference. This review describes key characteristics for each device type, explains differences in markers of lung deposition, lists potential advantages and disadvantages of the different devices and discusses how these and other factors need to be considered when selecting an inhaler device that meets the individual needs of a patient.
Export Options
About this article
Cite this article as:
Berger William, Aerosol Devices and Asthma Therapy, Current Drug Delivery 2009; 6 (1) . https://dx.doi.org/10.2174/156720109787048203
DOI https://dx.doi.org/10.2174/156720109787048203 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Bronchial Epithelial Cells in Allergic Reactions
Current Drug Targets - Inflammation & Allergy The Digenea Parasite Opisthorchis felineus: A Target for the Discovery and Development of Novel Drugs
Infectious Disorders - Drug Targets The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug
Letters in Drug Design & Discovery G Protein-Coupled Receptors and their Signaling Pathways: Classical Therapeutical Targets Susceptible to Novel Therapeutic Concepts
Current Pharmaceutical Design Vitamin D as a Potential Therapeutic Option in Cancer Treatment: Is There a Role for Chemoprevention?
Anti-Cancer Agents in Medicinal Chemistry From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) ADAMs and Ectododomain Proteolytic Shedding in Leucocyte Migration: Focus on L-Selectin and ADAM17
Current Immunology Reviews (Discontinued) A Review of <i>Saurauia roxburghii</i> Wall. (Actinidiacaea) as a Traditional Medicinal Plant, Its Phytochemical Study and Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Immunomodulatory Role of Vascular Endothelial Growth Factor and Angiopoietin-1 in Airway Remodeling
Current Molecular Medicine Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets The University of New Mexico Center for Molecular Discovery
Combinatorial Chemistry & High Throughput Screening Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews The Usefulness of the Multiple Allergen Simultaneous Test-Chemiluminescent as Compared to the Phadia Immunocap IgE Test Panel System in Children and Adolescents
Recent Patents on Inflammation & Allergy Drug Discovery From Hygiene Hypothesis to Novel Allergic Asthma Therapeutics
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents New Insights about Regulatory T Cells Distribution and Function with Exercise: The Role of Immunometabolism
Current Pharmaceutical Design Atopic Dermatitis and Cytokines: The Immunoregulatory and Therapeutic Implications of Cytokines in Atopic Dermatitis - Part II: Negative Regulation and Cytokine Therapy in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry Editorial: (Thematic Issue: Occupational Exposure: An Undermined Risk Factor of Lung Diseases in the Informal Sectors of Developing Economy)
Current Respiratory Medicine Reviews